Glaxosmithkline Pharmaceuticals Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2424 as of 06 May 16:01 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 16.8 on March 2021 to 27.3 on March 2025 . This represents a CAGR of 10.20% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1053 crore on March 2021 to ₹ 1885 crore on March 2025 . This represents a CAGR of 12.36% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 214.2 crore as compare to the Sep '25 revenue of ₹ 243.86 crore. This represent the decline of -12.16% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of SMS Pharmaceuticals Ltd for the Dec '25 is ₹ 47.4 crore as compare to the Sep '25 ebitda of ₹ 49.8 crore. This represent the decline of -4.82% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 23.19 crore over 7 quarters. This represents a CAGR of 22.02% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or SMS Pharmaceuticals Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,017 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,765 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd?

As of May 6, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2362.25. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹402.1.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.